Company intelligence / Profile preview
Microba Life Sciences
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 1
Overview
Microba has launched MetaPanel™, a world-first accredited metagenomic diagnostic test for gastrointestinal pathogens, now distributed in Australia through Sonic Healthcare. Clinical studies show MetaPanel detects over 60% more GI pathogens in IBD patients than routine methods, supporting its integration into standard care. The company is also advancing multiple preclinical therapeutic programs targeting chronic diseases using its proprietary microbiome platform.
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Live biotherapeutics (microbiome-based therapeutics)Metagenomic diagnostics and testing platforms
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Microba Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microba Life Sciences.